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 GCS mRNA levels 
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 Chronic 
 Progressive 
 Large spectrum of severity  
        & symptoms 
 
 
 
 
 
MPS III  
(= Sanfilippo Syndrome) 
  A, B, C and D 
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 cytotoxic effects?... 
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  No! 
  However,  
  some cytotoxic effects could occur in particular cell lines 
 
 Efficacy gSRT vs ERT and effect of combiatory 
treatment?... 
  Depends on specific features of each cell line 
  Thus,  
  the combined therapy might potentially result in various 
 effects in different patients 
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 lglycogen levels 
 
Tissue-specific effect 
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A LOOK FORWARD… 
 Vector  design & si/shRNA encapsulation 
 
  bioavailability of siRNAs; 
 protection from degradation 
 control of  
 circulation time 
 release rate  
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 Genotoxic evaluation of the  
    si/shRNA+nanocarrier formulation(s) 
 
 internalization 
 cell viability  
 genotoxic potential  
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A LOOK FORWARD… 
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THE OPEN QUESTIONS: 
 Delivery 
 Appropriate vector 
 Animal models 
 Recapitulate human disease 
 In vivo testing 
 Mode of administration 
 local? 
 Systemic? 
 Intravenous?  
 Intrathecal? 
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